Results 311 to 320 of about 1,467,646 (404)

T cell targeting in cancer therapy [PDF]

, 1991
Bolhuis, R.L.H. (Reinder), Braakman, E. (Eric), Sturm, E. (E.)   +2 more
core   +1 more source

Decoding MHC loss: Molecular mechanisms and implications for immune resistance in cancer

Clinical and Translational Medicine, Volume 15, Issue 7, July 2025.
Tumour cells evade immune surveillance by downregulating MHC expression through transcriptional repression, lysosomal degradation and post‐translational modifications. Pharmacological agents interventing epigenetic and metabolic can upregulate MHC expression and improve T cell activation.
Pei Lin, Yunfan Lin, Xu Chen, Xinyuan Zhao, Li Cui   +4 more
wiley   +1 more source

Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B-Cell Lymphoma. [PDF]

Clin Pharmacol Ther
Li T, Gibiansky L, Parikh A, Putnins M, Chiu CW, Sacchi M, Feng H, Ahmadi T, Gupta M, Xu S.   +9 more
europepmc   +1 more source

Cancer stem cells: Bridging microenvironmental interactions and clinical therapy

Clinical and Translational Medicine, Volume 15, Issue 7, July 2025.
Cancer stem cells (CSCs) drive tumor progression through their dynamic self‐renewal capacity, epigenetic plasticity, and drug resistance. These cells interact bi‐directionally with the tumor ecosystem to promote immunosuppressive reprogramming and metastatic spread.
Huiling Wang, Junshu Li, Fei Du, Hongxin Deng   +3 more
wiley   +1 more source

The Tumour Glyco‐Code: Sialylation as a Mediator of Stromal Cell Immunosuppression in the Tumour Microenvironment

European Journal of Immunology, Volume 55, Issue 7, July 2025.
The Sialic acid/Siglec axis is emerging as an important target in the TME. We explore the role of sialylation within stromal‐rich, immunosuppressive TMEs, focusing on how specific sialic acid/Siglec interactions dictate innate and adaptive immune responses.
Aoise O'Neill, Norashikin Zakaria, Hannah Egan, Oliver Treacy, Aisling M. Hogan, Michael O'Dwyer, Sean O. Hynes, Aideen E. Ryan   +7 more
wiley   +1 more source

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma. [PDF]

Blood Cancer J
Mohan M, Szabo A, Cheruvalath H, Clennon A, Bhatlapenumarthi V, Patwari A, Balev M, Bhutani D, Shrestha A, Thanendrarajan S, Dhakal B, Zangari M, Trikannad A, Vellanki S, Al-Hadidi S, Lentzsch S, van Rhee F, Bag A, D'Souza A, Shah N, Chakraborty R, Shah MR, Schinke C.   +22 more
europepmc   +1 more source

Retargeting of Human Regulatory T Cells by Single-Chain Bispecific Antibodies

, 2011
Stefanie Koristka, Marc Cartellieri, Anke Theil, Anja Feldmann, Claudia Arndt, Slava Stamova, Irene Michalk, Katrin Töpfer, Achim Temme, Karsten Kretschmer, Martin Bornhäuser, Gerhard Ehninger, Marc Schmitz, Michael Bachmann   +13 more
openalex   +1 more source

TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions

Hematological Oncology, Volume 43, Issue 4, July 2025.
ABSTRACT TP53‐mutated acute myeloid leukemia (AML) remains one of the most treatment‐resistant hematologic malignancies, with poor overall survival despite advancements in therapeutic strategies. The loss of functional p53 compromises DNA repair, apoptosis, and genomic stability, rendering both conventional and novel therapies largely ineffective. This
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Caterina Labanca, Giulio Caridà, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Noemi Puccio, Antonino Neri, Fortunato Morabito, Massimo Gentile   +11 more
wiley   +1 more source

NK cell depletion in bispecific antibody therapy is associated with lack of HIV control after ART interruption. [PDF]

Commun Biol
Sánchez-Gaona N, Perea D, Curran A, Burgos J, Navarro J, Suanzes P, Falcó V, Martín-Gayo E, Genescà M, Carrillo J, Buzón MJ.   +10 more
europepmc   +1 more source

Bystander CAR^-CD8⁺ T cells in a CAR-T cell product can expand and enhance the antitumor effects of a bispecific antibody. [PDF]

J Immunother Cancer
Kato J, Konishi T, Honda T, Maruta M, Nabe S, Masuda Y, Matsumoto M, Kawasaki N, Miyazaki Y, Doi Y, Takasuka Y, Yamanouchi J, Ochi T, Takenaka K.   +13 more
europepmc   +1 more source